Evidence map›Paper›PMID 36202813›Full record

ArticleNature communications2022

Predicting the structural basis of targeted protein degradation by integrating molecular dynamics simulations with structural mass spectrometry.

Tom Dixon, Derek MacPherson, Barmak Mostofian, Taras Dauzhenka, Samuel Lotz, Dwight McGee, Sharon Shechter, Utsab R Shrestha, Rafal Wiewiora, Zachary A McDargh and 23 more

Open access · goldAbstract read
In one paragraph

Article in Nature communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed
7.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 94 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Hydrogen-Deuterium Exchange Mass Spectrometry for Molecular Glue Characterization.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Article
  18. State-of-the-Art and Future Directions in Structural Proteomics.Molecular & cellular proteomics : MCP · 2025
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

33 authors at 2 institutions in 1 country.

Tom Dixon *Roivant Discovery, New York City, NY, 10036, USA.ORCID 0000-0002-4520-3894
Derek MacPherson *Roivant Discovery, New York City, NY, 10036, USA.ORCID 0000-0003-2006-1620
Barmak Mostofian *Roivant Discovery, New York City, NY, 10036, USA.ORCID 0000-0003-0568-9866
Taras DauzhenkaRoivant Discovery, New York City, NY, 10036, USA.ORCID 0000-0003-0771-7074
Samuel LotzRoivant Discovery, New York City, NY, 10036, USA.ORCID 0000-0001-6159-615X
Dwight McGeeRoivant Discovery, New York City, NY, 10036, USA.
Sharon ShechterRoivant Discovery, New York City, NY, 10036, USA.
Utsab R ShresthaRoivant Discovery, New York City, NY, 10036, USA.ORCID 0000-0001-6985-6657
Rafal WiewioraRoivant Discovery, New York City, NY, 10036, USA.
Zachary A McDarghRoivant Discovery, New York City, NY, 10036, USA.
Fen PeiRoivant Discovery, New York City, NY, 10036, USA.ORCID 0000-0003-4278-8265
Rajat PalRoivant Discovery, New York City, NY, 10036, USA.
João V RibeiroRoivant Discovery, New York City, NY, 10036, USA.ORCID 0000-0002-0353-4126
Tanner WilkersonRoivant Discovery, New York City, NY, 10036, USA.
Vipin SachdevaRoivant Discovery, New York City, NY, 10036, USA.
Ning GaoRoivant Discovery, New York City, NY, 10036, USA.
Shourya JainRoivant Discovery, New York City, NY, 10036, USA.
Samuel SparksRoivant Discovery, New York City, NY, 10036, USA.
Yunxing LiRoivant Discovery, New York City, NY, 10036, USA.
Alexander VinitskyRoivant Discovery, New York City, NY, 10036, USA.
Xin ZhangRoivant Discovery, New York City, NY, 10036, USA.ORCID 0000-0001-9901-1276
Asghar M RazaviRoivant Discovery, New York City, NY, 10036, USA.
István KolossváryRoivant Discovery, New York City, NY, 10036, USA.
Jason ImbriglioRoivant Discovery, New York City, NY, 10036, USA.
Artem EvdokimovRoivant Discovery, New York City, NY, 10036, USA.
Louise BergeronRoivant Discovery, New York City, NY, 10036, USA.
Wenchang ZhouRoivant Discovery, New York City, NY, 10036, USA.
Jagat AdhikariRoivant Discovery, New York City, NY, 10036, USA.ORCID 0000-0002-6295-645X
Benjamin RuprechtRoivant Discovery, New York City, NY, 10036, USA.
Alex DicksonDepartment of Computational Mathematics, Science, and Engineering, Michigan State University, East Lansing, MI, 48824, USA. alexrd@msu.edu.ORCID 0000-0002-9640-1380
Huafeng XuRoivant Discovery, New York City, NY, 10036, USA. huafeng.xu@roivant.com.ORCID 0000-0001-5447-0452
Woody ShermanRoivant Discovery, New York City, NY, 10036, USA. woody.sherman@roivant.com.
Jesus A IzaguirreRoivant Discovery, New York City, NY, 10036, USA. jesus.izaguirre@roivant.com.ORCID 0000-0002-4687-4884
Roivant Sciences (United States) · USMichigan State University · US

Funding

Revealing the Ligand Binding Landscape with Advanced Molecular Simulation MethodsR01GM130794 · NIGMS · MICHIGAN STATE UNIVERSITY · PI DICKSON, ALEXANDER · 2018 to 2025
$2.8M
NIGMS NIH HHS R01 GM130794
6 · The paper itself

Abstract

Targeted protein degradation (TPD) is a promising approach in drug discovery for degrading proteins implicated in diseases. A key step in this process is the formation of a ternary complex where a heterobifunctional molecule induces proximity of an E3 ligase to a protein of interest (POI), thus facilitating ubiquitin transfer to the POI. In this work, we characterize 3 steps in the TPD process. (1) We simulate the ternary complex formation of SMARCA2 bromodomain and VHL E3 ligase by combining hydrogen-deuterium exchange mass spectrometry with weighted ensemble molecular dynamics (MD). (2) We characterize the conformational heterogeneity of the ternary complex using Hamiltonian replica exchange simulations and small-angle X-ray scattering. (3) We assess the ubiquitination of the POI in the context of the full Cullin-RING Ligase, confirming experimental ubiquitinomics results. Differences in degradation efficiency can be explained by the proximity of lysine residues on the POI relative to ubiquitin.

Indexed as

Cullin ProteinsMolecular Dynamics SimulationDeuteriumLysineMass SpectrometryProteolysisUbiquitinUbiquitinationUbiquitin-Protein LigasesCullin ProteinsDeuteriumLysineUbiquitinUbiquitin-Protein Ligases

Identifiers

PMID36202813
PMCPMC9537307
OpenAlexW4302293700

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.